On August 17, WUXI XDC rose 4.11% in regular trading, trading at 64.7 HKD/share, with turnover of approximately 47.87 million HKD.

On the news front, the company previously announced that its board of directors will convene on August 24 to review and approve interim results for the six months ended June 30, fueling positive market expectations. Fellow WuXi-affiliated entity WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit attributable to shareholders up 29.43%, with management raising full-year guidance across the board, boosting overall sector sentiment.

On the institutional side, Schroders PLC increased its long position on August 6 at an average price of 55.3979 HKD per share, bringing its stake to 5.01%. Meanwhile, CLSA maintained an Outperform rating with a target price of 82.6 HKD, and Daiwa initiated coverage with a Buy rating and a 78 HKD target, naming the company a top CXO sector pick.

Within the Life Sciences Tools and Services sector, the broader sector strengthened. Among individual stocks, GENSCRIPT BIO up 5.06%, WUXI BIO up 4.61%, WUXI APPTEC up 4.05%, XTALPI up 2.8%, INSILICO up 2.69%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)